BACKGROUND: Data on the incidence, timing, and risk factors for herpes zoster (HZ) in heart transplant (HT) recipients are limited. METHODS: We determined HZ incidence rates and actuarial estimates of time to first HZ episode in 314 HT recipients at our institution from 1995 to 2010. We developed Cox models to assess potential risk factors for HZ in HT. RESULTS: Median age at HT was 54 (range, 17-71) years; 237 (76%) were male. There were 60 episodes of HZ in 51 patients, with an overall incidence rate of 31.6 cases (95% confidence interval [CI], 23.5-41.6)/1000 person-years. Although most cases occurred during the first post-HT year, cumulative HZ incidence was 0.078 at 1, 0.15 at 5, and 0.20 at 10 years. Many patients had substantial HZ morbidity, including 14% with HZ ophthalmicus and 45% with post-herpetic neuralgia. Adjusting for age, gender, and acute cellular rejection episodes, exposure to mycophenolate mofetil (MMF) was an independent risk factor for HZ (adjusted hazard ratio [HR] 2.18; 95% CI, 1.20-3.96; P = 0.01), while ganciclovir-based cytomegalovirus prophylaxis reduced HZ risk (adjusted HR 0.09; 95% CI, 0.01-0.71; P = 0.02). Although age and female gender increased HZ risk, the magnitude of their effect was not statistically significant in Cox models. CONCLUSIONS: HZ is common and morbid after HT, particularly with MMF exposure. Ganciclovir prophylaxis is effective in reducing the short-term risk of HZ, but the steady incidence of cases for years post HT makes long-term HZ prevention challenging. Augmenting varicella zoster virus immunity post HT with vaccines warrants further exploration.
BACKGROUND: Data on the incidence, timing, and risk factors for herpes zoster (HZ) in heart transplant (HT) recipients are limited. METHODS: We determined HZ incidence rates and actuarial estimates of time to first HZ episode in 314 HT recipients at our institution from 1995 to 2010. We developed Cox models to assess potential risk factors for HZ in HT. RESULTS: Median age at HT was 54 (range, 17-71) years; 237 (76%) were male. There were 60 episodes of HZ in 51 patients, with an overall incidence rate of 31.6 cases (95% confidence interval [CI], 23.5-41.6)/1000 person-years. Although most cases occurred during the first post-HT year, cumulative HZ incidence was 0.078 at 1, 0.15 at 5, and 0.20 at 10 years. Many patients had substantial HZ morbidity, including 14% with HZ ophthalmicus and 45% with post-herpetic neuralgia. Adjusting for age, gender, and acute cellular rejection episodes, exposure to mycophenolate mofetil (MMF) was an independent risk factor for HZ (adjusted hazard ratio [HR] 2.18; 95% CI, 1.20-3.96; P = 0.01), while ganciclovir-based cytomegalovirus prophylaxis reduced HZ risk (adjusted HR 0.09; 95% CI, 0.01-0.71; P = 0.02). Although age and female gender increased HZ risk, the magnitude of their effect was not statistically significant in Cox models. CONCLUSIONS: HZ is common and morbid after HT, particularly with MMF exposure. Ganciclovir prophylaxis is effective in reducing the short-term risk of HZ, but the steady incidence of cases for years post HT makes long-term HZ prevention challenging. Augmenting varicella zoster virus immunity post HT with vaccines warrants further exploration.
Authors: Atsuko Hata; Hideomi Asanuma; Mary Rinki; Margaret Sharp; Ruby M Wong; Karl Blume; Ann M Arvin Journal: N Engl J Med Date: 2002-07-04 Impact factor: 91.245
Authors: J Ignacio Herrero; Jorge Quiroga; Bruno Sangro; Fernando Pardo; Fernando Rotellar; Javier Alvarez-Cienfuegos; Jesus Prieto Journal: Liver Transpl Date: 2004-09 Impact factor: 5.799
Authors: Michał J Figurski; Tomasz Pawiński; Lee R Goldberg; David DeNofrio; Artur Nawrocki; David O Taylor; Kathleen D Lake; Donna Chojnowski; Leslie M Shaw Journal: Ann Transplant Date: 2012 Jan-Mar Impact factor: 1.530
Authors: P J H Smak Gregoor; T van Gelder; I C van Riemsdijk-van Overbeeke; A C T M Vossen; J N M IJzermans; W Weimar Journal: Transpl Infect Dis Date: 2003-06 Impact factor: 2.228
Authors: R Lauzurica; B Bayés; C Frías; N Fontseré; A Hernandez; L Matas; A Jimenez; J Bonet; R Romero Journal: Transplant Proc Date: 2003-08 Impact factor: 1.066
Authors: S Cabezón Ruiz; J M Cisneros; E Lage Galle; A Ordóñez; R F Hinojosa; J E Morán Risco; A Hernández Journal: Transplant Proc Date: 2003-08 Impact factor: 1.066
Authors: Ricardo M La Hoz; Ashley Wallace; Nicolas Barros; Donglu Xie; Linda S Hynan; Terrence Liu; Christina Yek; Scott Schexnayder; Justin L Grodin; Sonia Garg; Mark H Drazner; Matthias Peltz; Robert W Haley; David E Greenberg Journal: Transpl Infect Dis Date: 2020-12-09
Authors: Lei Wang; Erik A M Verschuuren; Coretta C van Leer-Buter; Stephan J L Bakker; Anoek A E de Joode; Johanna Westra; Nicolaas A Bos Journal: Front Immunol Date: 2018-07-16 Impact factor: 7.561